OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.
W Janni(University Hospital Ulm), FJ Sapunar(GlaxoSmithKline (Croatia)), K Schwedler(GlaxoSmithKline (Croatia)), Tomasz Sarosiek, C. Papadimitriou(GlaxoSmithKline (Croatia)), Williams Ls(GlaxoSmithKline (Croatia)), Joanna Pikiel(Chemotherapy Foundation), Michele Caruso(Humanitas Mater Domini), Bogusława Karaszewska(State University of Applied Sciences in Konin), Kathryn Jane Briggs(GlaxoSmithKline (United Kingdom)), R. Hervé(GlaxoSmithKline (Croatia)), MR Lau(GlaxoSmithKline (Croatia)), Gallego J Alavarez(GlaxoSmithKline (Croatia))
Cited by 1
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k